PUBLIC RELEASE DATE:

27-May-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 27, 2014The commonly used food additive monosodium glutamate (MSG) has been linked to obesity and disorders associated with the metabolic syndrome including progressive liver disease. A new study that identifies MSG as a critical factor in the initiation of obesity and shows that a restrictive diet cannot counteract this effect but can slow the progression of related liver disease is published in Journal of Medicinal Food, a peer-reviewed journal from Mary Ann Liebert, Inc.. The paper is available on the Journal of Medicinal Food website.

Makoto Fujimoto and a team of international researchers from Japan, the U.S., and Italy monitored the weight gain and development of nonalcoholic fatty liver disease and its progression to nonalcoholic steatohepatitis in MSG-treated mice fed either a calorie-restricted or regular diet. They report their findings in the article "A Dietary Restriction Influences the Progression But Not the Initiation of MSG-Induced Nonalcoholic Steatohepatitis".

"Although MSG has been deemed a safe food additive, its dosage, interaction with other drugs, effects on vulnerable populations, and effects on chronic inflammatory diseases and neurological diseases are unknown," says Co-Editor-in-Chief Sampath Parthasarathy, MBA, PhD, Florida Hospital Chair in Cardiovascular Sciences, University of Central Florida, Orlando, in the Editorial "How Safe is Monosodium Glutamate? Exploring the Link to Obesity, Metabolic Disorders, and Inflammatory Disease" . The findings by Fujimoto et al. "may have far reaching implications, as childhood obesity is a major problem across the globe."

###

About the Journal

Journal of Medicinal Food is an authoritative, peer-reviewed, multidisciplinary journal published monthly in print and online. Led by Editors-in-Chief Sampath Parthasarathy, MBA, PhD, and Young-Eun Lee, PhD, Wonkwang University, Jeonbuk, Korea, this scientific journal for leaders of the nutraceutical and functional foods revolution publishes original scientific research on the bioactive substances of functional and medicinal foods, nutraceuticals, herbal substances, and other natural products. The Journal explores the chemistry and biochemistry of these substances, as well as the methods for their extraction and analysis, the use of biomarkers and other methods to assay their biological roles, and the development of bioactive substances for commercial use. Tables of content and a free sample issue may be viewed on the Journal of Medicinal Food website.

About the Publisher

See the article here:
What what role does MSG play in obesity and fatty liver disease?

President Barack Obama quizzed students on their robots, electric cars, genetic discoveries and other projects at the White House science fair, highlighting the administrations push to boost science, technology, engineering and matheducation.

U.S. companies have lamented a shortfall of workers trained in so-called STEM fields, and the government officials want to boost enrollment in such programs.

These are the fields of the future, Mr.Obama said.This is where the good jobs are going to be.

As part of the fair, Mr. Obama announced $35 million in Department of Education grants to support training of more science, engineering and math teachers, an expansion of the AmeriCorps STEM program and a mentoring plan to link tech workers with students.

The White House said 100 students from more than 30 states came to the fair.On the same day of a major announcement about Afghanistan, a call with Ukraines president-elect and developments in policy toward Syria, the president spent more than an hour visiting with some of the students and asking them about award-winning projects.

Were so proud of you, Mr. Obama told 18-year-oldElana Simonof New York City. Ms. Simon, who survived a rare form of liver cancer, discovered a link between a common genetic mutation and the illness.

Peyton Robertson, a 12-year-old from Fort Lauderdale, Fla., developed a sandless sandbag to help protect against flooding. When dry, my bags are really lightweight, they weigh only four pounds, Mr. Robertson told the president. But then when you add water it expands and becomes heavy, it weighs 30 pounds.

Some tweets from the event:

See original here:
Obama Quizzes Kid Geniuses at White House Science Fair

Crowd marches against genetic engineering of food
Crowd marches against genetic engineering of food.

By: reddingnews

Read the original post:

Crowd marches against genetic engineering of food - Video

How Genetic Engineering Can Cure Drug Addiction? Michael Crichton on Treatment (2006)
Genetic engineering, also called genetic modification, is the direct manipulation of an organism #39;s genome using biotechnology. New DNA may be inserted in the host genome by first isolating...

By: Remember This

Read the rest here:

How Genetic Engineering Can Cure Drug Addiction? Michael Crichton on Treatment (2006) - Video

Object Oriented Programming
In object oriented programming, "Objects" usually refer to bundles of information. For example, you can describe a Car as having #39;number_of_wheels = 4 #39; and #39;license_plate = 4BIUO11 #39;, and this...

By: J. Christopher Anderson

Originally posted here:

Object Oriented Programming - Video

PUBLIC RELEASE DATE:

26-May-2014

Contact: Philippa Walker 44-117-928-8086 University of Bristol

An international team of scientists has made a major step forward in our understanding of how enzymes 'edit' genes, paving the way for correcting genetic diseases in patients.

Researchers at the Universities of Bristol, Mnster and the Lithuanian Institute of Biotechnology have observed the process by which a class of enzymes called CRISPR pronounced 'crisper' bind and alter the structure of DNA.

The results, published in the Proceedings of the National Academy of Sciences (PNAS) today, provide a vital piece of the puzzle if these genome editing tools are ultimately going to be used to correct genetic diseases in humans.

CRISPR enzymes were first discovered in bacteria in the 1980s as an immune defence used by bacteria against invading viruses. Scientists have more recently shown that one type of CRISPR enzyme Cas9 can be used to edit the human genome - the complete set of genetic information for humans.

These enzymes have been tailored to accurately target a single combination of letters within the three billion base pairs of the DNA molecule. This is the equivalent of correcting a single misspelt word in a 23-volume encyclopaedia.

To find this needle in a haystack, CRISPR enzymes use a molecule of RNA - a nucleic acid similar in structure to DNA. The targeting process requires the CRISPR enzymes to pull apart the DNA strands and insert the RNA to form a sequence-specific structure called an 'R-loop'.

The global team tested the R-loop model using specially modified microscopes in which single DNA molecules are stretched in a magnetic field. By altering the twisting force on the DNA, the researchers could directly monitor R-loop formation events by individual CRISPR enzymes.

Read this article:

Breakthrough shows how DNA is 'edited' to correct genetic diseases

PUBLIC RELEASE DATE:

26-May-2014

Contact: Philippa Walker 44-117-928-8086 University of Bristol

An international team of scientists has made a major step forward in our understanding of how enzymes 'edit' genes, paving the way for correcting genetic diseases in patients.

Researchers at the Universities of Bristol, Mnster and the Lithuanian Institute of Biotechnology have observed the process by which a class of enzymes called CRISPR pronounced 'crisper' bind and alter the structure of DNA.

The results, published in the Proceedings of the National Academy of Sciences (PNAS) today, provide a vital piece of the puzzle if these genome editing tools are ultimately going to be used to correct genetic diseases in humans.

CRISPR enzymes were first discovered in bacteria in the 1980s as an immune defence used by bacteria against invading viruses. Scientists have more recently shown that one type of CRISPR enzyme Cas9 can be used to edit the human genome - the complete set of genetic information for humans.

These enzymes have been tailored to accurately target a single combination of letters within the three billion base pairs of the DNA molecule. This is the equivalent of correcting a single misspelt word in a 23-volume encyclopaedia.

To find this needle in a haystack, CRISPR enzymes use a molecule of RNA - a nucleic acid similar in structure to DNA. The targeting process requires the CRISPR enzymes to pull apart the DNA strands and insert the RNA to form a sequence-specific structure called an 'R-loop'.

The global team tested the R-loop model using specially modified microscopes in which single DNA molecules are stretched in a magnetic field. By altering the twisting force on the DNA, the researchers could directly monitor R-loop formation events by individual CRISPR enzymes.

See the rest here:
Breakthrough shows how DNA is 'edited' to correct genetic diseases

Genetic Engineering...allowed to what extent?
To what extent the Genetic Engineering is allowed? #39; #39; #39; #39;

By: Waqf Nau Canada

Read more:
Genetic Engineering...allowed to what extent? - Video

Scotch Moses: Genetic Engineering
For more from Scotch Moses, subscribe to their channel: http://www.youtube.com/subscription_center?add_user=scotchmosesofficial A pregnant couple decides just how much to mess with mother...

By: Funny Or Die

See original here:
Scotch Moses: Genetic Engineering - Video

Court decision keeps NZ GE-free

A recent High Court decision is a victory for New Zealand consumers, farmers and foresters, says the Soil & Health Association. The High Court ruled against a decision by the Environmental Protection Authority (EPA) that two new plant breeding techniques were not genetic engineering techniques.

Soil & Health welcomes the court ruling. Without it New Zealand would have lost its status and international reputation as a producer of GE-free food and fibre.

If the EPAs decision had not been challenged and found wanting, plants bred using these GE techniques could have been planted in New Zealand without any public consultation or monitoring of their effects, said Marion Thomson, co-chair of Soil & Health.

There are other new techniques like this, and they must all be thoroughly and independently scrutinised and the precautionary principle applied. Otherwise, its an uncontrolled experiment that could have adverse effects for people, animals and the environment.

The High Court ruled that the EPA had misinterpreted the law and that it had failed to apply the precautionary principle.

Soil & Health is concerned about the ability of the EPA to protect our environment, says Thomson. We commend the Sustainability Council for challenging the EPAs decision, but we should not have to rely on not-for-profit watchdog organisations to protect our environment. That is the job of the EPA, and we urge them to apply the precautionary principle in any similar decisions in future.

Soil & Health has been informing its members and the public about genetic engineering for over 25 years. It has played a key role in advocating for a GE-free New Zealand for health, environmental, economic and other reasons. The New Zealand public, and our key markets, have consistently opposed genetic engineering in food and the environment.

ENDS

Scoop Media

Read more:
Court decision keeps NZ GE-free

PUBLIC RELEASE DATE:

22-May-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 22, 2014To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords of animal models of SMA. A new study demonstrating that enough copies of the SMN1 gene can be delivered to the spinal cord motor neurons to extend the survival of the treated animals is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.

Marco Passini and coauthors from Genzyme (Framingham, MA), University of California San Francisco, Emory University School of Medicine (Atlanta, GA), and Georgetown University Medical Center (Washington, DC) used an adeno-associated viral vector as the delivery vehicle to transport copies of the SMN1 gene into motor neurons in the spinal cord via intrathecal delivery. They report on the effectiveness of restoring the levels of functional SMN protein in normal pig and non-human primate SMA models that would predict efficacy based on gene transfer with the same vector in an authentic mouse model of SMA in the article "Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9Survival Motor Neuron 1 for Spinal Muscular Atrophy."

"This is a very promising and thorough set of preclinical studies that supports rapid translation to the clinic," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

###

About the Journal

Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

More:
Gene therapy extends survival in an animal model of spinal muscular atrophy

Solestia - Genetic Engineering

By: BeyondTheBeyond

Go here to see the original:

Solestia - Genetic Engineering - Video

Locals Radio-Dr Thierry Vrain-Genetic Engineer speaks on the horrors of GMO #39;s and Roundup
Dr. Thierry Vrain, former genetic engineer and soil biologist with Agriculture Canada, spoke with us today about his concerns with genetically engineered crops (GMOs) and more importantly,...

By: Kevin Proteau

Read more here:

Locals Radio-Dr Thierry Vrain-Genetic Engineer speaks on the horrors of GMO's and Roundup - Video

Genetic Engineering And Cloning

By: Android Tablet

Read the original here:

Genetic Engineering And Cloning - Video

LW Genetic Engineering

By: Liz Wigdahl

Read more from the original source:

LW Genetic Engineering - Video

PUBLIC RELEASE DATE:

21-May-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 21, 2014A targeted gene silencing strategy blocks production of the dysfunctional huntingtin (Htt) protein, the cause of Huntington's disease, a fatal, inherited neurodegenerative disorder. The effectiveness of this RNA interference (RNAi) approach in reducing levels of mutant Htt protein and disease symptoms in a mouse model of the disease is described in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.

Lisa Stanek and coauthors from Genzyme (Framingham, MA) used an adeno-associated viral (AAV) vector to deliver a targeted nucleic acid sequence called a small interfering RNA (siRNA) into the cells of affected mice. The siRNA selectively binds to the mutated gene, blocking disease-causing Htt production. The authors present data demonstrating the ability to deliver the therapeutic RNAi into the cells, reduce mutant Htt levels, and impact behavioral deficits in the mice without causing any noticeable neurotoxicity, in their article "Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease."

"The Genzyme group uses state-of-the-art delivery technology and a gene silencing approach to generate very promising preclinical data for Huntington's disease," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

###

About the Journal

Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

Excerpt from:
Novel RNAi therapy silences mutated Huntington's disease gene and reduces symptoms

DNA, cloning, and genetic engineering
via YouTube Capture.

By: Lindsey Jackson

Continued here:
DNA, cloning, and genetic engineering - Video

PUBLIC RELEASE DATE:

20-May-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 20, 2014Studies have identified mobile phones and related devices as sources of metal sensitization and potential causes of allergic contact dermatitis (ACD). Despite efforts to control allergen release in phones, many phones on the market release levels of metals, such as nickel and chromium, which are sufficient to induce ACD, according to an article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers. The article is available free on the Pediatric Allergy, Immunology, and Pulmonology website at http://online.liebertpub.com/doi/full/10.1089/ped.2013.0308.

In the article "Mobile Phone Dermatitis in Children and Adults: A Review of the Literature," a team of researchers led by Jacob Thyssen, MD, PhD, Copenhagen University Hospital Gentofte (Hellerup, Denmark), Loma Linda University School of Medicine (Loma Linda, CA), and University of Arizona College of Medicine (Phoenix, AZ), review the current literature on mobile phone dermatitis in both children and adults. Nickel sensitization is common in children, resulting in ACD prevalence levels of up to 33%. This information is important for practitioners, particularly when evaluating patients with dermatitis of the face, neck, hands, breast, or anterior thighscommon places exposed to cell phones. The authors provide important diagnostic tips for practitioners and strategies to raise awareness of nickel- or chromium-induced mobile phone ACD.

"With the rising use of cell phones and other mobile devices, pediatricians can expect to see additional cases of ACD," says Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook (Stony Brook, NY) and practicing pediatric pulmonologist at Winthrop University Hospital. "Thyssen's paper discusses diagnostic patch testing for common metal allergens and the value of spot testing of the patient's phone in establishing a causal relationship."

###

About the Journal

Pediatric Allergy, Immunology, and Pulmonology is a quarterly peer-reviewed journal published in online with Open Access options and in print. The Journal synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. The Journal provides comprehensive coverage to further the understanding, and optimize the treatment, of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a sample issue may be viewed on the Pediatric Allergy, Immunology, and Pulmonology website at http://www.liebertpub.com/ped.

About the Publisher

See the article here:
Can mobile phones cause allergic reactions?

Req ID: 7661

Overview: Marathon Oil Corporation is an international energy company engaged in exploration and production; oil sands mining;and integrated gas.

Marathon Oil has a major leasehold position in the core of the Eagle Ford Shale formation in South Texas.

The Company holds acreage in the Eagle Ford, focusing on Atascosa, DeWitt, Gonzales, and Karnes counties.

Marathon Oil's Eagle Ford Subsurface team is seeking an Engineering Technician to support our Kenedy group.

The successful candidate will support the Eagle Ford subsurface team primarily with company operated assets.

The candidate will be expected to work closely with multidisciplinary teams and management in support of a variety of development activities and functions.

This position will report to a Subsurface Manager for the Eagle Ford Asset Team and will be located in Houston.

Responsibilities:

Preferred Qualifications:

Originally posted here:
Engineering Technician Job

Early genetic engineering experiment

By: Rafa_el

See the original post here:

Early genetic engineering experiment - Video